1. Recommendations for breast cancer screening in Brazil, from the Brazilian College of Radiology and Diagnostic Imaging, the Brazilian Society of Mastology, and the Brazilian Federation of Gynecology and Obstetrics Associations.
- Author
-
Delle Urban, Linei Augusta Brolini, Chala, Luciano Fernandes, de Paula, Ivie Braga, di Pace Bauab, Selma, Schaefer, Marcela Brisighelli, Kefalás Oliveira, Ana Lúcia, Shimizu, Carlos, des Gonçalves de Oliveira, Tatiane Men, de Camargo Moraes, Paula, Maranhão Miranda, Beatriz Medicis, Aduan, Flávia Engel, de Jesus Fonseca Rego, Salete, de Oliveira Canella, Ellyete, Couto, Henrique Lima, Badan, Gustavo Machado, Esteves-Francisco, José Luis, Moraes, Thaís Paiva, Jakubiak, Rosangela Requi, and Peixoto, João Emílio
- Subjects
- *
BREAST , *MAGNETIC resonance mammography , *CINAHL database , *MAGNETIC resonance imaging , *EARLY detection of cancer , *DIAGNOSTIC imaging , *SCIENTIFIC literature , *SCIENCE in literature , *MEDLINE - Abstract
Objective: To present an update of the recommendations of the Brazilian College of Radiology and Diagnostic Imaging, the Brazilian Society of Mastology, and the Brazilian Federation of Gynecology and Obstetrics Associations for breast cancer screening in Brazil. Materials and Methods: Scientific evidence published between January 2012 and July 2022 was gathered from the following databases: Medline (PubMed); Excerpta Medica (Embase); Cochrane Library; Ebsco; Cumulative Index to Nursing and Allied Health Literature (Cinahl); and Latin-American and Caribbean Health Sciences Literature (Lilacs). Recommendations were based on that evidence and were arrived at by consensus of a joint committee of experts from the three entities. Recommendations: Annual mammographic screening is recommended for women between 40 and 74 years of age. For women at or above the age of 75, screening should be reserved for those with a life expectancy greater than seven years. Women at higher than average risk are considered by category: those with dense breasts; those with a personal history of atypical lobular hyperplasia, classical lobular carcinoma in situ, or atypical ductal hyperplasia; those previously treated for breast cancer; those having undergone thoracic radiotherapy before age 30; and those with a relevant genetic mutation or a strong family history. The benefits of complementary screening are also addressed according to the subcategories above. The use of tomosynthesis, which is an evolved form of mammography, should be considered in screening, whenever accessible and available. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF